Longitudinal Prevalence of Major Eye Diseases

Lee, Paul P.; Feldman, Zachary W; Ostermann, Jan; Brown, Derek S.; Sloan, Frank A.

doi:10.1001/archopht.121.9.1303

Cited by 128 publications

(92 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…high IOP, absence of a visual test, baring of the blind spot, case records, unstandardised criteria) were used in five studies (19%). [100][101][102][103][104] IOP, diabetes and myopia status were obtained from a secure record (examination or examination records) in most studies. However, only one (20%) 105 obtained family history status from a secure source, by examination of firstdegree relatives of detected cases.…”

Section: Quality Of Available Evidencementioning

confidence: 99%

See 1 more Smart Citation

The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation

Burr¹,

Mowatt²,

Hernández³

et al. 2007

Health Technol Assess

330

380

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

Section: Quality Of Available Evidencementioning

confidence: 99%

“…21,22,28,63,64,99,[105][106][107][108][109][110][111][112][113][114][115][116][117] All but one of the included studies 105 described a population-based cross-sectional study. The remaining eight studies [100][101][102][103][104][118][119][120] are also described in Appendix 6.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation

Burr¹,

Mowatt²,

Hernández³

et al. 2007

Health Technol Assess

330

380

View full text Add to dashboard Cite

show abstract

“…1 Such diseases can include age-related macular degeneration, affecting 5% to 27% of health-plan beneficiaries, proliferative diabetic retinopathy, affecting 14.5% to 25.6% of patients with diabetes mellitus, 2 and other less prevalent diseases, such as StevensJohnson syndrome, with 2.2 to 7.1 cases per million inhabitants. 3 Bevacizumab, a monoclonal antibody that binds to all VEGF isoforms, was developed to treat colorectal cancer, 4 and its use for ocular diseases has not yet been approved by the United States Food and Drug Administration (FDA).…”

Section: Introductionmentioning

confidence: 99%

Bevacizumab for ocular neovascular diseases: a systematic review

et al. 2009

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Many eye diseases involve increased local levels of vascular endothelial growth factor (VEGF), and there are several therapeutic strategies for them. Thus, the aim of this study was to evaluate the effectiveness and safety of bevacizumab for treating eye diseases involving increased local levels of VEGF, as the assumed pathophysiological mechanism. DATA SOURCES:The following databases were systematically searched for evidence: PubMed, CENTRAL (Cochrane Library), Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) and reference lists, without language restrictions. Only randomized controlled trials were included. The primary outcome of interest was visual acuity, irrespective of the evaluation method.DATA SYNTHESIS: A total of 667 eyes in nine randomized trials were included. Meta-analysis showed that the proportion of patients with age-related macular degeneration who presented improvements from baseline regarding best-corrected visual acuity was higher among those treated with bevacizumab than among those in the photodynamic therapy group (risk ratio, RR, 0.49; 95% confidence interval, CI, 0.31 to 0.78; P = 0.01). CONCLUSIONS:The evidence available demonstrates that bevacizumab alone or combined with other treatments is more effective than other options, including photodynamic therapy, focal photocoagulation and triamcinolone. The use of bevacizumab instead of photodynamic therapy could reduce treatment costs by more than 99% and could significantly increase access to treatment. However, long-term studies are still needed in order to reduce uncertainty concerning the safety of this medication for all ocular neovascular diseases in which bevacizumab has the potential to improve visual acuity. CONCLUSÕES: A evidência disponível demonstra que bevacizumabe isolado ou combinado com outras terapias é mais eficaz que terapia fotodinâmica, fotocoagulação focal e triancinolona. O uso de bevacizumabe em vez da terapia fotodinâmica poderia reduzir os custos do tratamento em mais de 99% e aumentar significativamente o acesso ao tratamento. Entretanto, o aspecto de segurança do fármaco ainda necessita ser avaliado por estudos em longo prazo com todas as doenças neovasculares em que bevacizumabe tenha o potencial de melhorar acuidade visual.

show abstract

“…Epidemiological estimates suggest that the prevalence of ARMD will increase all over the world as the elderly population becomes proportionally larger (3) . And an incidence rate increase of 5% to 27% over a 9-year period was reported in the USA (4) .…”

Section: Introductionmentioning

confidence: 98%

Prevalence of age-related macular degeneration in Japanese immigrants and their descendants living in Londrina (PR) - Brazil

Oguido¹,

Casella²,

Matsuo³

et al. 2008

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Longitudinal Prevalence of Major Eye Diseases

Abstract: To describe the prevalence across time of 3 chronic eye diseases among a representative cohort of elderly subjects.

Cited by 128 publications

References 40 publications

The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation

Bevacizumab for ocular neovascular diseases: a systematic review

Prevalence of age-related macular degeneration in Japanese immigrants and their descendants living in Londrina (PR) - Brazil

Contact Info

Product

Resources

About